The United Kingdom and the United States have hammered out a major bilateral deal that will maintain no tariffs on UK medicine exports being sold in the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to raise funding on medicines through the National Health Service (NHS). This move secures that duties on these crucial goods will stay at nothing for a duration of three years.
This deal comes after previous threats to dramatically increase duties on branded drug imports, with potential rates discussed reaching 100%.
"This arrangement between the UK bolsters the worldwide climate for cutting-edge drugs and establishes much-needed equity to American-British drug exports," a statement noted.
Economic Significance
Medicines represent one of the Britain's biggest goods shipped to the US, which is easily the primary buyer for large British pharmaceutical firms.
Statistics reveal that in the one-year period leading up to September, the UK sold medicines valued at £11.1bn to the US. This amount accounted for a significant portion of total UK exports in that period.
"This deal secures jobs, stimulates investment and paves the way for the UK to emerge as a worldwide center for life sciences," a government official commented.
Key British Pledges
The agreement includes several notable pledges from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to double total NHS spending on treatments from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The amount manufacturers must refund to the NHS to stay within budget will be limited at 15%. In the past, refunds topped 20%.
Recent Tensions
The pact comes amid a long-running tension between the sector and the British authorities over spending levels and regulatory access.
This friction were intensified by assertions that US consumers were paying significantly more for the equivalent treatments than people in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been announced toward projects in the United States.
One official acknowledged that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had declined as a share of its resources over the past decade.
